1. HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis, Marry van den Heuvel-Eibrink, Christian M. Zwaan, Andrew L. Kung, and Scott A. Armstrong Blood Volume 113(11):2375-2385 March 12, 2009 ©2009 by American Society of Hematology

2. ShRNA-mediated knockdown of HOXA9 expression in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells and murine leukemia stem cells (L-GMP). Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology

3. Analysis of phenotypic consequences after shRNA-mediated HOXA9 suppression in t(9;11) MOLM-14 AML and t(4;11) SEMK2 ALL cells. Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology

4. Effects of HOXA9 suppression in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells. Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology

5. Induction of apoptosis by HOXA9 suppression is significantly correlated with the presence of the MLL-fusion oncogene. Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology

6. HOXA9 suppression induces apoptosis in primary MLL-rearranged human AML cells. Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology

7. Assessment of the effects of HOXA9 suppression in vivo using bioluminescent imaging. Joerg Faber et al. Blood 2009;113:2375-2385 ©2009 by American Society of Hematology